Browse
Submit Data
Databases
API
Help

Dataset Information

14 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A single center and single arm study for personalized neoantigen peptides vaccine in the treatment of advanced colorectal cancer

ABSTRACT: Interventions: Case series:Case series Primary outcome(s): Safety Index;ORR;PFS;OS;immune indexes;EORTC QLQ-C30 V3.0;DCR Study Design: Single arm

DISEASE(S): Colorectal Cancer

PROVIDER: 2683387 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Impact of Anamorelin with unresectable pancreatic, gastric and colorectal cancer patients for a quality of life, skeletal muscle index and malnutrition

Project description:Primary outcome(s): Difference in QOL between non-Anamorelin usage and Anamorelin usage patients in 24 weeks (assessed by EORTC QLQ-C30)

| 2661537 | ecrin-mdr-crc

Outcome in Colorectal Cancer: Identification of Differences and Measures for Nationwide Quality Development

Project description:Interventions: Group 1: The patients are interviewed on the basis of an internationally recognized questionnaire (EORTC QLQ-30 and QLQ-C29) on their general well-being and physical fitness, on mental health problems and on physical problems. The survey takes place at two measuring times: before therapy and once again after 12 months. The total duration of the study is three years. Primary outcome(s): health-related quality of life measured by EORTC QLQ-C30 and QLQ-CR29; pretherapeutically and once again posttherapeutically after 12 months Study Design: Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: other

| 2431299 | ecrin-mdr-crc

A prospective study of irinotecan drug-eluting beads (DEBIRI) combined with FOLFIRI in patients after failure of FOLFOX with colorectal liver metastases

Project description:Interventions: Case Series:DEBIRI+FOLFIRI Primary outcome(s): DCR Study Design: Case series

| 2679864 | ecrin-mdr-crc

A single arm trial of cetuximab, FOLFIRI combined with NK as the second line region in metastatic K-ras positive colorectal cancer: the XQZL001 study

Project description:Interventions: 1:cetuximab, FOLFIRI combined with NK as the second line remedy Primary outcome(s): disease control rate, DCR;Objective Response Rate Study Design: Case series

| 2668928 | ecrin-mdr-crc

Examination of relationship between quality of life and adverse events in the first -line treatment including cetuximab for KRAS wild-type unresectable colorectal cancer

Project description:Interventions: QoL assessment for the patient treated with 1st line cetuximab containing regimen Primary outcome(s): 1. correlation between skin toxicity +/- other adverse events and QoL 2. correlation between efficacy and skin toxicity 3. correlation between efficacy and QoL 4. concordance between DLQI and EORTC QLQ-C30 Study Design: Single arm Non-randomized

| 2626361 | ecrin-mdr-crc

Third-line therapy with apatinib in metastatic colorectal cancer: individualized dose adjustment based on plasma concentration and adverse reactions

Project description:Interventions: single arm:apatinib Primary outcome(s): DCR;PFS Study Design: Case series

| 2676440 | ecrin-mdr-crc

A Study Evaluating Xilonix in Symptomatic Colorectal Cancer Patients Refractory To Standard Therapy

Project description:Primary Efficacy Endpoint: • The primary endpoint of this study will be the objective response rate (ORR), a composite measure consisting of change in lean body mass (LBM) and change in quality of life, from screening to week 8. The ORR will be defined as a stabilization or positive (≥0 kg) change in lean body mass (LBM)—as assessed by dual-energy X-ray absorptiometry (DEXA) scan, and improvement or no worsening (≥0 score point change) on any two of the three symptom scale measures (fatigue, pain, appetite) of EORTC QLQ-C30. Primary endpoints: The primary endpoint of this study will be the objective response rate (ORR), a composite measure consisting of change in lean body mass (LBM) and change in quality of life, from screening to week 8. The ORR will be defined as a stabilization or positive (≥0 kg) change in lean body mass (LBM)—as assessed by dual-energy X-ray absorptiometry (DEXA) scan, and improvement or no worsening (≥0 score point change) on any two of the three symptom scale measures (fatigue, pain, appetite) of EORTC QLQ-C30.

| 2532982 | ecrin-mdr-crc

Single cell RNA-sequencing of T cells to examine barcode swapping

Project description:T cells from OT-I mice were stimulated with 4 different peptide ligands for 6 hours and sorted into two 96-well plates. Cells on each plate were barcoded using a mutually exclusive 8-by-12 set of indexes, such that indexes present on plate 1 were completely absent from plate 2 and vice versa. Libraries from each plate were pooled in equimolar quantities and sequenced on an Illumina HiSeq 4000. Libraries were demultiplexed allowing for all pairs of indexes, including the expected combinations (pairs of barcodes used within each plate) and unexpected combinations (pairs containing one barcode from each plate). This was repeated after sequencing the same pool of libraries on the HiSeq 2500.

2018-06-21 | E-MTAB-6843 | biostudies-arrayexpress

Study of the changes in bowel movements after surgery for rectal cancer and how it affects the quality of life of such patients.

Project description:Intervention1: LARS score: All patients who undergo had undergone low anterior resection for rectal cancer in Regional Cancer, one year before will be interviewed by a trained interviewer twice at 3-6 months interval using Wexner Incontinence Score 2.LARS Malayalam Questionnaire 3.EORTC QLQ C30 and CR 29 Malayalam translations for measuring QOL. Primary outcome(s): Incidence of LARS syndrome in patients undergoing low anterior resection for rectal cancer.Timepoint: Post surgery, 3 months and 6 months post op.

| 2595345 | ecrin-mdr-crc

Capecitabine Plus Aflibercept as Maintenance Therapy Following Capecitabine Plus Oxaliplatin Plus Aflibercept in Patients With Metastatic Colorectal Cancer

Project description:Primary Objective: Efficacy: To assess the progression-free survival rate at 10 months in patients on maintenance therapy with capecitabine plus aflibercept. Secondary Objectives: To evaluate: * Efficacy: Progression Free Survival (PFS) * Efficacy: Overall Survival (OS) * Efficacy: Objective Response Rate (ORR) as per Response Evaluation Criteria In Solid Tumors (RECIST version 1.1) criteria * Health related Quality of Life (HRQL): EORTC QLQ-C30 scores and EQ5D-3L * Safety Exploratory Objective: To collect blood and tumor samples to perform investigations for potential biomarker testing.

| 2162511 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data